7
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Identification of a Novel Nonsense Mutation in the Ligand-Binding Domain of the Vitamin D Receptor Gene and Clinical Description of Two Greek Patients with Hereditary Vitamin D-Resistant Rickets and Alopecia

      case-report

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background/Aims: We analyzed the vitamin D receptor (VDR) gene in 2 Greek patients who exhibited the classical features of hereditary vitamin D-resistant rickets (HVDRR) type II, including severe bone deformities and alopecia. We also describe the clinical phenotypes and the response to treatment of our patients. Methods: Genomic DNA was extracted from peripheral blood samples of both patients. Coding region and flanking introns of VDR gDNA was amplified and direct sequenced. Results: A unique cytosine to thymine (C>T) transition was identified at nucleotide position 1066 (c.1066C>T) in the ligand-binding domain of the VDR gene of both patients, predicting the substitution of a glutamine to a terminal codon at position 356 (Gln356stop). Conclusions: The novel nonsense mutation c.1066C>T (Gln356stop) is expected to result in a VDR protein 71 amino acids shorter and thus to affect the normal VDR function. In particular, the missing protein part alters the VDR heterodimerization with the retinoid X receptor which has been correlated with the presence of alopecia. Both patients were introduced to treatment with supraphysiological doses of 1α-calcidiol which improved their clinical phenotypes except for alopecia.

          Related collections

          Most cited references34

          • Record: found
          • Abstract: found
          • Article: not found

          The nonskeletal effects of vitamin D: an Endocrine Society scientific statement.

          Significant controversy has emerged over the last decade concerning the effects of vitamin D on skeletal and nonskeletal tissues. The demonstration that the vitamin D receptor is expressed in virtually all cells of the body and the growing body of observational data supporting a relationship of serum 25-hydroxyvitamin D to chronic metabolic, cardiovascular, and neoplastic diseases have led to widespread utilization of vitamin D supplementation for the prevention and treatment of numerous disorders. In this paper, we review both the basic and clinical aspects of vitamin D in relation to nonskeletal organ systems. We begin by focusing on the molecular aspects of vitamin D, primarily by examining the structure and function of the vitamin D receptor. This is followed by a systematic review according to tissue type of the inherent biological plausibility, the strength of the observational data, and the levels of evidence that support or refute an association between vitamin D levels or supplementation and maternal/child health as well as various disease states. Although observational studies support a strong case for an association between vitamin D and musculoskeletal, cardiovascular, neoplastic, and metabolic disorders, there remains a paucity of large-scale and long-term randomized clinical trials. Thus, at this time, more studies are needed to definitively conclude that vitamin D can offer preventive and therapeutic benefits across a wide range of physiological states and chronic nonskeletal disorders.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The direct role of vitamin D on bone homeostasis.

            Vitamin D requires two metabolic conversions, 25-hydroxylation in the liver and 1alpha-hydroxylation in the kidney, before its hormonal form, 1,25-dihydroxyvitamin D [1,25-(OH)2D], can bind to the vitamin D receptor (VDR) to modulate gene transcription and regulate mineral ion homeostasis. The receptor and metabolic enzymes are expressed in many tissues, however, which has long suggested that the vitamin D hormone could act in an autocrine, paracrine, or intracrine fashion to affect the biology of non-classical target tissues. Strong support for this model has been obtained for Toll-like receptor-mediated innate immunity in macrophages, for example. The classical view is that vitamin D exerts its effects on bone indirectly via control of calcium and phosphate homeostasis, despite expression of cyp27b1, the 25-hydroxyvitamin D-1alpha-hydroxylase, and the VDR in osteoblasts and chondrocytes. Recent molecular genetic studies have revealed direct, but non-essential roles for 1,25-(OH)2D in growth plate chondrocytes. Specific inactivation of the VDR in collagen type II-expressing chondrocytes leads to reduced RANKL expression and delayed osteoclastogenesis, which causes a transient increase in bone volume at the primary spongiosa. Chondrocyte-specific VDR-ablated mice also show reduced circulating levels of FGF23 and thus elevated serum phosphate concentrations. The mechanisms remain to be completely determined but appear to involve a 1,25-(OH)2D-induced secreted factor from chondrocytes that affects FGF23 production by neighboring osteoblasts. The phenotype of additional mutant mice models, including chondrocyte-specific inactivation or overexpression of cyp27b1, is being analyzed to provide further support for these results that show autocrine and paracrine roles for 1,25-(OH)2D during endochondral bone development.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              The vitamin D receptor and the syndrome of hereditary 1,25-dihydroxyvitamin D-resistant rickets.

                Bookmark

                Author and article information

                Journal
                HRP
                Horm Res Paediatr
                10.1159/issn.1663-2818
                Hormone Research in Paediatrics
                S. Karger AG
                1663-2818
                1663-2826
                2014
                September 2014
                23 July 2014
                : 82
                : 3
                : 206-212
                Affiliations
                aThird Department of Pediatrics, Athens University Medical School, ‘Attikon' University General Hospital, bDepartment of Bone and Mineral Metabolism, Institute of Child Health, ‘Agia Sophia' Children's Hospital, and cResearch Laboratory of the Musculoskeletal System ‘Th. Garofalidis', University of Athens, ‘KAT' Hospital, Athens, Greece
                Author notes
                *Anna Papadopoulou, DEA, PhD, Third Department of Pediatrics, Athens University Medical School, ‘Attikon' University General Hospital, 1 Rimini Street, Haidari, GR-12464 Athens (Greece), E-Mail anpapado@med.uoa.gr
                Article
                362618 Horm Res Paediatr 2014;82:206-212
                10.1159/000362618
                25060608
                baf603c7-5ba8-434d-b09e-19999036c821
                © 2014 S. Karger AG, Basel

                Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

                History
                : 05 November 2013
                : 01 April 2014
                Page count
                Figures: 3, Tables: 1, Pages: 7
                Categories
                Novel Insights from Clinical Practice

                Endocrinology & Diabetes,Neurology,Nutrition & Dietetics,Sexual medicine,Internal medicine,Pharmacology & Pharmaceutical medicine
                Hormone resistance,Nonsense mutation,Hereditary vitamin D-resistant rickets,Vitamin D receptor ,1,25-Dihydroxyvitamin D

                Comments

                Comment on this article